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Abstract: For viruses to productively infect their hosts, they must evade or inhibit 
important elements of the innate immune system, namely the type I interferon (IFN) 
response, which negatively influences the subsequent development of antigen-specific 
adaptive immunity against those viruses. Dengue virus (DENV) can inhibit both type I IFN 
production and signaling in susceptible human cells, including dendritic cells (DCs). The 
NS2B3 protease complex of DENV functions as an antagonist of type I IFN production,  
and its proteolytic activity is necessary for this function. DENV also encodes proteins that 
antagonize type I IFN signaling, including NS2A, NS4A, NS4B and NS5 by targeting 
different components of this signaling pathway, such as STATs. Importantly, the ability of 
the NS5 protein to bind and degrade STAT2 contributes to the limited host tropism of DENV 
to humans and non-human primates. In this review, we will evaluate the contribution of 
innate immunity evasion by DENV to the pathogenesis and host tropism of this virus. 
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1. Introduction 
Innate immunity and type I IFN responses function as the first line of defense against viral infections. 
Most viruses target these important elements to avoid being sensed or recognized in infected cells and  
to efficiently establish infection in the host. Several viruses have been shown to inhibit type I IFN 
production in infected cells, but it has been shown only recently by our group that DENV can target the 
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IFN production pathway in infected cells as an additional immune evasion strategy. On the other hand, 
several DENV proteins have been identified in recent years to be involved in the inhibition of type I 
IFN signaling in infected cells. By inhibiting this important pathway, the virus is able to stop the 
induction of hundreds of IFN inducible genes with antiviral functions that may impair several aspects 
of the virus cycle. 
DENV is a human pathogen that productively infects a wide range of cells involved in the immune 
response. It has been demonstrated that DENV replicates in monocytes, macrophages, B cells, and 
dendritic cells (DCs) among others. DCs are professional antigen-presenting cells (APCs) and also 
some of the first cells that interact with DENV upon the bite of an infected mosquito [30,35,36,71]. 
This encounter favors the internalization of DENV by receptor-mediated endocytosis after the adhesion of 
the structural E protein with cellular receptors such as dendritic cell-specific intracellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN). Acidification of endosomes induces an irreversible 
conformational change of the E protein, resulting in the fusion of endosomal and viral membranes 
followed by the release of the nucleocapsid into the cytoplasm. The DENV genome is composed of a 
single-stranded positive-sense RNA molecule that is translated into a single polyprotein of approximately 
3391 amino acids. After translation, the polyprotein localizes within the ER membrane where it is 
cleaved by the viral protease complex, NS2B3, and cellular proteases to generate three structural proteins 
[capsid (C), premembrane/membrane (prM/M) and envelop (E)] and seven non-structural proteins 
(NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). Some non-structural proteins have the ability to 
modify the ER membrane, creating the micro-environment necessary for the synthesis of new viral 
products. The assembly of these viral products invokes the formation of virions, which are 
subsequently exocytosed via Golgi-derived secretory vesicles. 
In the present review, we discuss the recent reports that have shown and defined the possible 
mechanisms of inhibition of both the production and signaling of type I IFN by DENV. We also 
discuss the implications of DENV’s evasion of this important innate immunity mechanism on the 
development of antiviral drugs or animal models for this important human pathogen. 
2. Discussion 
2.1. Inhibition of Type I IFN Production by DENV 
The accumulation of pathogen-associated molecular patterns (PAMPs) like the viral intermediate 
double-stranded RNA (dsRNA), facilitates virus detection by a series of host pathogen recognition 
receptors (PRRs) leading to the activation of professional APCs. The most relevant PRRs for the 
detection of DENV products, described so far are the membrane-bound Toll-like receptors 
(TLR3/TLR7/TLR8) and the cytosolic receptors (RIG-I/MDA-5) [43,50,65]. As with other intracellular 
pathogens, these PAMP/PRR interactions trigger a cascade of events that ends with the expression of a 
series of cytokines and chemokines of paramount importance for the control of the infection. Several 
groups have demonstrated that DENV is a weaker inducer of type I IFN responses after infection of 
human dendritic cells, with a minimal production of IFNα/β [27,57,61] especially compared to other 
viral infections that competently induce significant levels of these fundamental cytokines, as is the case 
for Newcastle disease virus (NDV) [20] and Semliki Forest virus (SFV) [25]. The absence of type I Viruses 2012, 4                  
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IFN production by DENV-infected DCs results in an impaired ability of those   
DCs to prime T cells toward Th1 immunity, an effect that can be reversed by the addition of exogenous  
IFNβ [57]. Interestingly, DENV is able to trigger the expression of some proinflammatory cytokines (IL-
6, IL-8, TNFα, and MIP-1β), a phenomenon observed at early times after infection. An explanation  
for this hallmark feature of DENV is that the virus acquired, through evolution, a strategy to attract 
target cells to the site of infection by allowing the expression of some chemoattractant molecules by 
infected cells.  
DENV has successfully evolved to overcome host innate immunity and productively infect the host 
using a balanced combination of two fundamental strategies (Figure 1), one is passively, by evading 
the interaction of PAMPs with the cellular PRRs, and the other is actively, by the inhibition of 
different steps of the innate immune response through the expression of antagonist molecules which 
directly block the intracellular pathways that lead to type I IFN production and signaling.  
Figure 1. Model for inhibition of type I interferon (IFN) production by DENV: Dengue 
virus (DENV) can inhibit the induction of type I IFN using different strategies. The NS2B3 
protease complex targets and cleaves still unidentified components of the type I IFN 
production pathway leading to the interruption of IRF3 phosphorylation. Furthermore, 
DENV can evade encounter with cellular sensors by hiding its replication products in 
ER-derived membranes.  
 
2.1.1. Passive Evasion of PRR Detection 
DENV infection provokes virus-induced intracellular membrane structures including vesicle 
packets (VPs) and convoluted membranes (CMs) [13]. This intracellular arrangement provides   
a physical framework that concentrates the host and viral components required for virus replication. 
VPs are ER-bound vesicles of about 3.5 × 10
−4 μm
3 that contain multiple non-structural proteins, 
double-stranded RNA and de novo synthesized RNA and are connected by pores to the   
cytoplasm [21,44,69]. This spatial rearrangement creates a microenvironment that is partially   
isolated from the cytosol and some of its components. This feature, which is common to many other 
positive-sense RNA viruses, not only promotes the concentration of viral products necessary for 
replication, but also precludes the physical interaction with the host PRRs. This phenomenon could Viruses 2012, 4                  
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delay the PRR-PAMP interaction until the replication process synthesizes enough viral products for the 
constitution of the new progeny, a strategy also described for other flaviviruses [21]. In parallel, 
another important element in the evasion strategy is the conserved viral RNA conformation. DENV 
RNA secondary structure has an impact on replication in both mosquito and mammalian hosts [2].  
Cis-acting elements required for RNA synthesis and translation initiation can be found at the 5′UTR 
and the 3′UTR of the viral genome [67]. Also, the RNA secondary structure at the flavivirus 3′UTR 
provides resistance to cellular RNases and promotes the accumulation of sub-genomic RNA with 
implications for cytopathicity in cell culture as well as pathogenicity in mice [22]. These specific 
conformations acquired through viral evolution could also be implicated in the poor detection of 
DENV by the PRRs. The rational modification of these structures at the untranslated regions by point 
mutations or deletions would be an interesting approach to evaluate the viral RNA/PRR interaction. 
2.1.2. Active Inhibition of Type I IFN Production by DENV  
Frequently, viruses are able to express proteins that interfere with the type I IFN response. A few of 
them in particular, can actively inhibit the production of IFN-α/β using this strategy. Some of the most 
studied are the influenza A NS1 protein [23] and the VP35 protein of Ebola virus [6]. In the case  
of DENV, our group demonstrated, using a primary human cell system, that infection of human DCs  
with DENV did not induce IRF-3 phosphorylation, resulting in an inhibition of type I IFN production 
after DENV infection [58] (Figure 2). A subsequent report, also by our group, explored the ability of 
DENV-infected DCs to respond to a variety of type I IFN-triggering signals using potent stimulators 
such as NDV, SeV, SFV, or TLR3 ligand poly(I:C) [57] (illustrated in Figure 2). These two studies, 
demonstrated that DENV-infected DCs failed to produce type I IFN and that these have reduced type I 
IFN production upon secondary infection or stimulation. This effect is viral dose dependent and takes 
place as early as 2 hours after DENV infection. We also showed that the inhibition of IFNα/β 
production after NDV infection in DENV-infected DCs is not a bystander effect, implying an active 
role of the DENV-infected DC population in the inhibition of IFNα/β. By using an NDV vector 
strategy to express the DENV non-structural proteins (NS2A, NS2B3, NS4A and NS4B), it was shown 
that the only recombinant NDV that triggered diminished IFNα expression was the one carrying   
the NS2B3 protease complex. Similar results were seen using an IFNβ promoter activity assay [57]. 
Catalytically inactive NS2B3 mutants showed a diminished inhibition of this phenotype, suggesting an 
important role for the protease activity of the NS2B3 protein as an innate immunity antagonist [57]. 
Interestingly, the proteolytic core of NS2B3, consisting of the last 40 amino acids of NS2B and   
the first 180 amino acids of NS3, was enough to reduce the activity of the IFNβ promoter [57]. Further 
studies are needed to decipher the exact mechanism of inhibition of type I IFN production by DENV  
in infected cells and to identify the host partners that are involved in this inhibition. Identification of 
host factors that contribute to this inhibition by interacting with or by being cleaved by DENV NS2B3 
protease will be crucial for the design of antiviral drugs and intervention steps for DENV infection. 
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Figure 2. Inhibition of type I IFN production by DENV: The recognition of DENV 
replication intermediates by the cytosolic helicases, RIG-I and MDA-5, induces a 
conformational change that promotes the interaction between the caspase-recruitment 
domain (CARD) of these pattern-recognition receptors and the CARD-containing adaptor, 
MAVS. Furthermore, the membrane-bound protein, Toll-like receptor 3 (TLR3), binds 
dsRNA in endosomes, inducing the activation of the adaptor protein, TRIF. All of these 
pathways converge in the recruitment and activation of the IKKε/TBK-1 complex. This 
activation induces phosphorylation and homo- and hetero-dimerization of transcription 
factors, IRF3 and IRF7, which translocate to the nucleus to induce the expression of type I 
interferon together with activated NF-κB and AP-1. The DENV protease complex inhibits 
the phosphorylation of IRF3 thereby resulting in a lack of type I IFN production in human 
dendritic cells. 
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2.2. Inhibition of Type I IFN Signaling by DENV  
Figure 3. Inhibition of type I IFN signaling by DENV: IFNα/β binds the type I IFN 
receptor (IFNAR), which is composed of IFNAR1 and IFNAR2 and is found on the 
surface of nucleated cells. Receptor binding triggers tyrosine autophosphorylation of the 
Janus kinases, Jak1 and Tyk2. The activated kinases then phosphorylate STAT1 and STAT2. 
Activated STAT2, which is normally associated with IFN regulatory factor 9 (IRF9), 
associates with activated STAT1 to form the trimeric IFN-stimulated gene factor 3 (ISGF3) 
complex, which translocates to the nucleus and binds to the IFN-stimulated response element 
(ISRE) of IFN-stimulated genes (ISGs). Hundreds of ISGs are transcribed, and their products 
set up an antiviral state in the IFN-treated cell. DENV antagonizes this signaling pathway by 
utilizing NS5 to degrade STAT2, and by using NS2A, NS4A and NS4B to inhibit steps 
upstream of STAT1 activation.  
 Viruses 2012, 4                  
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Type I IFN signaling is initiated when IFN/ binds to type I IFN receptors (IFNAR) that are 
present on the surface of most cells. This results in the activation of the receptor-associated tyrosine 
kinases, Janus kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2), which subsequently phosphorylate signal 
transducer and activator of transcription 1 (STAT1) and signal transducer and activator of transcription 
2 (STAT2). Phosphorylated STAT1 and STAT2 along with interferon regulatory factor 9 (IRF9) form 
a heterotrimeric complex known as IFN-stimulated gene factor 3 (ISGF3) that translocates to the 
nucleus and binds the IFN-stimulated response element (ISRE) found upstream of IFN-stimulated genes 
(ISGs) [11] (Figure 3). Hundreds of ISGs exist, and many of their products have been shown to possess 
antiviral activities. These include protein kinase R(PKR), viperin, the 2′,5′-oligoadenylate synthetase 
(OAS) family and the IFN-induced transmembrane protein (IFITM) family. The importance of type I 
IFN signaling in controlling DENV replication and disease is emphasized by experiments conducted in 
IFNAR knock out (KO) mice and STAT2 KO mice [5,32,55,60]. Though wild-type mice are unable to 
support DENV replication, DENV can replicate in IFNAR KO and STAT2 KO mice. High viral loads 
and dengue disease symptoms are only seen in mice that lack both the type I and type II IFN pathways, 
indicating that the type II IFN response is also important in limiting viral replication [9,32,55,60]. 
DENV inhibits IFN/ signaling, and its NS2A, NS4A, NS4B and NS5 proteins have been implicated 
in this process [4,45,48,49]. 
Type II IFN signaling is distinct from type I IFN signaling. Type II IFN or IFN gamma (IFN) is 
produced only by immune cells, and binds the IFN receptor (IFNGR), which is located on a variety of 
cell types. Binding of IFN to its receptor leads to the activation of receptor-associated Jak1 and Jak2. 
This results in the phosphorylation of STAT1 and the formation of a STAT1 homodimer called   
IFN-activated factor (GAF), which translocates to the nucleus and binds to the IFN-activated sites 
(GAS) in a subset of genes [11]. This gene subset contains many of the genes that are activated by  
type I IFN signaling, but some genes are exclusively activated by only one of the IFN-signaling 
cascades [12,14]. Though there is strong evidence for DENV-mediated inhibition of IFN/ signaling, 
IFN-signaling does not appear to be targeted by the virus [26,33,66]. This contrasts with related 
viruses such as West Nile virus (WNV) and Langat virus (LGTV) that inhibit both pathways [7,42].  
Many of the type I IFN signaling components are also shared by the type III IFN response. In this 
signaling cascade, type III IFN or IFN lambda (IFN) binds to its receptor (IL10R and IL28R), 
which though structurally different from IFNAR, is also associated with Jak1 and Tyk2 and results  
in the formation of ISGF3 when activated [3]. Unlike IFNAR, IL28R is found only on a subset of  
cells [74]. The contribution of type III IFN to DENV host responses has not been studied though type  
III IFN has recently emerged as a determinant of patient outcomes during infection with another 
Flaviviridae family member, hepatitis C virus [24,62,64]. It is currently unknown if DENV antagonizes 
type III IFN signaling. 
2.2.1. Pretreatment with Type I IFN Can Inhibit DENV 
Though DENV can replicate in cells if IFN treatment occurs post infection, IFN/ inhibits   
DENV replication if it is added prior to infection [15,16]. This inhibition is independent of PKR and 
RNaseL since PKR and RNaseL double knockout mouse embryonic fibroblasts (MEFs) inhibited 
DENV replication as well as wild-type MEFs [15]. A variety of ISGs have been implicated in DENV Viruses 2012, 4                  
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suppression. Overexpression of viperin, an ISG that is highly expressed during DENV infection, 
inhibits DENV replication in A549 cells. Tumor necrosis factor-related apoptosis inducing ligand 
(TRAIL), which is induced by type I IFN signaling and upregulated during DENV infection, inhibits 
DENV replication in human dendritic cells [68]. IFITM1, IFITM2 and IFITM3 restrict early steps in 
both DENV and WNV replication [8]. Jiang and colleagues recently confirmed PKR’s irrelevance  
in IFN-mediated inhibition of DENV replication, as well as the involvement of viperin, IFITM2 and 
IFITM3 in virus inhibition [31]. They also identified ISG20 as an inhibitor of DENV replication [31]. 
Many previously uncharacterized ISGs have now been shown to inhibit flaviviruses such as yellow 
fever virus (YFV) and WNV [59]. It is likely that other ISGs that inhibit DENV will be identified as 
more of them are screened. 
2.2.2. DENV Inhibits Type I IFN Signaling 
When various cell lines were pretreated with IFN/, IFN or a combination of both, replication of 
several low- and high-passage DENV 2 strains was inhibited [16]. Interestingly, the effect of IFN and 
IFN were far more inhibitory than the effects of IFN, and the virus appeared to escape most of this 
inhibition if cells were infected prior to IFN/ treatment. Several reports have shown that human and 
non-human primate cells infected with DENV or harboring dengue replicons have decreased type I 
IFN signaling [4,26,33,45,49]. 
Infection with DENV decreases type I IFN-mediated STAT1 phosphorylation and also causes a 
proteasome-dependent decrease in STAT2 protein levels [4,26,33,49]. Type I IFN-induced STAT1 
phosphorylation was reduced in DENV2-infected A549 cells [49] and DENV2-infected K562   
cells [33]. K562 cells containing a DENV2 replicon have decreased STAT1 phosphorylation as well as 
decreased STAT2 levels [33,45]. Vero cells containing a DENV1 replicon or infected with DENV2 
also showed a decrease in STAT2 levels, and this decrease was proteasome-dependent [4]. A decrease 
in Tyk2 and STAT1 phosphorylation has also been documented in DENV2-infected dendritic cells 
though no STAT2 degradation was observed in that study [26]. The variation observed with regards to 
STAT1 phosphorylation, Tyk2 phosphorylation and STAT2 degradation may be due to the levels of 
viral replication in different cell types as well as virus strain and cell-type dependent differences. In 
fact, A549 and HepG2 cells showed differential type I IFN responses to two DENV2 strains, NGC and 
TSVO1, with NGC but not TSV01, inhibiting STAT1 phosphorylation [66]. Furthermore, though 
NGC-induced STAT2 degradation was not observed in A549 and HepG2 cells in that paper, Jones and 
colleagues showed that NGC induced STAT2 degradation in K562, supporting the idea of cell-type 
specific differences [33]. Though strain and cell-type dependent differences do appear to exist, there are 
three common observations seen when DENV infects human and non-human primate cells: type I IFN 
signaling is impaired, type I IFN-mediated STAT1 phosphorylation is inhibited, and total STAT2 protein 
levels decrease. We will now explore the contribution of different viral proteins to these processes. 
DENV encodes at least four proteins that inhibit type I IFN signaling (illustrated in Figure 3). 
Consequently, it can replicate in type I IFN-treated cells when cells are treated post infection [16]. This 
section will discuss how DENV inhibits type I IFN signaling through the use of the nonstructural 
proteins NS2A, NS4A, NS4B and NS5. We will also describe the contribution of NS5-mediated IFN Viruses 2012, 4                  
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antagonism to the limited host tropism of the virus, and how our understanding of this phenomenon 
may eventually lead to the development of an immune-competent mouse model of dengue infection. 
2.2.2.1. NS2A-, NS4A- and NS4B-Mediated Inhibition of STAT1 Phosphorylation 
Flavivirus NS2A, NS4A and NS4B are small hydrophobic proteins that associate with cellular 
membranes. DENV NS2A is thought to be involved in virus assembly because of its sequence similarity 
to NS2A proteins of Kunjin (KUN) virus and yellow fever virus (YFV), which are required for virion 
assembly [38,40]. DENV NS4A induces the membranous structures that house the viral replication 
complexes and colocalizes with dsRNA and structural protein E [46]. DENV NS4B also colocalizes 
with E and dsRNA suggesting that it is a part of the replication complex [47].  In addition to their roles 
in viral replication, NS2A, NS4A and NS4B of DENV have also been implicated in IFN signaling 
inhibition [48,49]. 
DENV-infected A549 cells have decreased STAT1 phosphorylation and IFN-induced ISRE-promoter 
activation [49]. This effect could be recapitulated when NS2A, NS4A and NS4B were expressed 
individually in cells, with NS4B inhibiting the pathway most potently. A more potent antagonistic effect 
was seen when the proteins were expressed together. NS4B’s ability to inhibit IFN signaling depends on 
its proper targeting to the ER membrane by the 2K protein [48]. NS4B proteins from other flaviviruses 
also inhibit type I IFN signaling [19,48]. Interestingly, a WNV NS4B mutation that decreased inhibition 
of type I IFN-signaling when overexpressed from a plasmid or in the context of a replicon had no IFN 
signaling antagonist defect in the context of the full virus [19]. Thus, with regards to IFN signaling 
inhibition, interplay between viral proteins exists during WNV infection, and this may also be the case 
for DENV. 
2.2.2.2. NS5-Mediated Degradation of STAT2  
Flavivirus NS5 is a 105-kDa protein that encodes an RNA guanylyltransferase, a methyltransferase 
(MTase) and an RNA-dependent RNA polymerase (RdRp). The N-terminus encodes an RNA 
guanylyltransferase that, in conjunction with NS3, initiates 5′ cap formation starting with a GTP 
substrate [29]. The N-terminus also encodes a methyltransferase that methylates guanine N-7 and 
ribose 2′-O of the viral RNA cap [17,18]. In both DENV and WNV, N-7 methylation has been shown 
to be more critical for viral replication than 2′-O methylation [17,73]. WNV mutants that lack 2′-O 
methylation function are sensitive to the antiviral effects of the IFN-induced tetratricopeptide repeat 
(IFIT) family members [10]. These data indicate that WNV NS5 inhibits the antiviral actions of a 
subset of ISGs, and can also be considered an ISG antagonist. This may also be the case for DENV 
NS5 since 2′-O methylation mutants similar to those in WNV also show replication defects [17]. The 
carboxy terminal region of NS5 interacts with the NS3 protein [34] and encodes the RdRp domain of 
DENV [1,51,63]. The multifunctional role of NS5 is demonstrated with mutants that lack one function  
but retain others. For example, an NS5 mutant can lack NS3 binding capabilities while retaining enzymatic 
activity, and other mutations inhibit viral replication while maintaining polymerase function [28,75]. 
Differential phosphorylation of NS5 may serve as a switch between these functions [34]. 
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Figure 4. Potential mechanisms for NS5-mediated STAT2 degradation: STAT2 degradation 
requires that NS5 be cleaved at its amino terminus. (A) During infection, cleavage of NS5 
may activate NS5 to direct STAT2 to an E3 ligase which would then target STAT2 to the 
proteasome for degradation; (B) Alternatively, the NS5 precursor may associate with an E3 
ligase and STAT2, and subsequent cleavage of NS5 away from NS4B would trigger E3 
ligase activation and STAT2 degradation. 
 
The NS5 proteins of several flaviviruses have been shown to inhibit IFN signaling. These   
include Langat virus, tick-borne encephalitis virus, Japanese encephalitis virus, DENV and West   
Nile virus [4,7,39,41,45,54,70]. DENV NS5 antagonizes IFN signaling by binding and degrading 
STAT2. When NS5 is expressed during virus infection, during replicon replication, or from a plasmid 
encoding NS1 through 5, cellular STAT2 levels diminish [4,33,45]. This observation was attributed to 
NS5 since constructs expressing all of the nonstructural proteins but NS5 were unable to decrease 
STAT2 levels [4]. NS5 binds STAT2 and inhibits type I IFN signaling when it is expressed alone but 
is unable to mediate STAT2 degradation [4,45] (Figure 4). Ashour and colleagues ascribed this to a 
difference between NS5 that is proteolytically cleaved from a precursor protein versus NS5 that is 
produced alone from a plasmid [4]. During a viral infection, NS5 is cleaved away from NS4B by 
NS2B3 protease. The researchers observed STAT2 degradation in cells expressing NS5 downstream of 
a NS2B3 protease cleavage recognition site in conjunction with NS2B3 protease, or NS5 downstream 
of a tobacco etch virus (TEV) protease recognition cleavage site in conjunction with TEV protease. 
STAT2 degradation also occurred in cells expressing NS5 downstream of ubiquitin. Because ubiquitin is 
cleaved away from downstream sequences by cellular hydrolases, a ubiquitin-NS5 construct produces a Viruses 2012, 4                  
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cleaved NS5 protein that resembles that seen during DENV infection. Thus STAT2 degradation requires 
that NS5 is cleaved at the amino terminus but is independent of the protease used to cleave NS5 [4]. 
During infection, cleaved NS5 may direct STAT2 to an E3 ligase that targets it to the proteasome  
for degradation. Alternatively, the NS5 precursor may associate with an E3 ligase and STAT2, and 
subsequent cleavage of NS5 away from NS4B could activate STAT2 degradation (Figure 4). 
2.2.3. Type I IFN Contributes to the Limited Host Tropism of DENV 
Though DENV replicates in humans and causes hemorrhagic disease, it is unable to do so in mice 
unless they lack components of the IFN response. DENV is able to replicate in mice that lack receptors 
for type I IFN signaling, or the type I signaling component STAT2 [5,32,55,60]. However, optimal 
replication and hemorrhagic symptoms are only seen when both the type I and type II IFN responses 
are dismantled [55,60]. The ability of DENV to inhibit human but not murine type I IFN can be 
explained by the affinity of NS5 for human STAT2 (hSTAT2) but not murine STAT2 (mSTAT2) [5]. 
This is reminiscent of parainfluenza virus 5 (formerly known as simian virus 5) that antagonizes type I 
IFN signaling in human cells but not in murine cells, because the viral V protein can associate with 
hSTAT2 but not mSTAT2 to target STAT1 for degradation [52]. When STAT2-deficient human cells 
are reconstituted with mSTAT2, they are inhibitory to DENV replication in an IFN/-dependent 
manner. However, when the cells are reconstituted with hSTAT2, DENV replication is not inhibited. 
Furthermore, when STAT2-deficient MEFs were reconstituted with hSTAT2, dengue replication was 
unaffected by IFN/ treatment, but it was inhibited in MEFs expressing mSTAT2 [5]. This suggests 
that it may be possible for DENV to replicate in mice that express hSTAT2 in place of mSTAT2, 
especially since STAT2-deficient mice allow replication of DENV [5,55].  
Because hSTAT2 allows parainfluenza virus 5 V protein to target STAT1 and inhibit type I IFN 
signaling, mice that ectopically express hSTAT2 support replication of parainfluenza virus 5 [37]. 
Since mSTAT2 is inhibitory to DENV replication, such a mouse would not support DENV replication. 
A mouse with hSTAT2 and no mSTAT2 may however support DENV replication, and would be 
immune-competent, since mSTAT2 and hSTAT2 are interchangeable for IFN signaling and ISG 
production [53]. The most widely used model of dengue infection, the AG129 mouse, lacks both type I 
and type II IFN signaling, so the contribution of the innate immune system to the development and 
resolution of dengue infections cannot be readily studied [56,72]. Humanized mice that are engrafted 
with CD34+ human cells form a human-like immune system, and do support the replication of DENV, 
but engraftment is highly variable [72]. A clonal population of immune-competent mice that are 
susceptible to DENV infection would be a valuable tool for investigating dengue infections, allowing 
researchers to study both immunology and immunopathology. A knock-in mouse expressing human 
STAT2 in place of murine STAT2 would likely be immune-competent and would likely allow 
replication of DENV as is seen in STAT2 KO mice. This animal could serve as a platform for 
investigation of the other causes of viral restriction namely the type II IFN response, eventually 
leading to the development of an immune-competent mouse model of dengue disease. 
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3. General Conclusions 
The combination of effective inhibition of type I IFN production and signaling in infected cells and 
effective modulation of DC activation by DENV may contribute to the induction of suboptimal adaptive 
immunity in patients. Additionally, DENV efficiently evades immune recognition by limiting the 
exposure of genetic RNA, which would be strongly detected by viral sensors in infected cells. Another 
possible hypothesis is that DENV has evolved to contain specific RNA structures that are poorly 
detected by those sensors. In conclusion, DENV is very efficient at modulating innate immunity and this 
property allows the virus to successfully establish infection in humans. Understanding the early events 
that occur when DENV interacts with and infects antigen-presenting cells such as DCs will provide 
crucial information for the design of strong antivirals and vaccines against this important pathogen. Also, 
the identification of host factors targeted by DENV for the inhibition of type I IFN responses will 
prove very useful for the development of immune-competent animal models for dengue disease. 
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